Patents Issued in August 15, 2019
-
Publication number: 20190248896Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: ApplicationFiled: April 29, 2019Publication date: August 15, 2019Inventors: Petrus Johannes Louis Spee, Soeren Berg Padkaer
-
Publication number: 20190248897Abstract: Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3.Type: ApplicationFiled: January 24, 2019Publication date: August 15, 2019Inventors: Gordon Yiu Kon Ng, Surjit Bhimarao Dixit, Thomas Spreter von Kruedenstein, Nina E. Weisser
-
Publication number: 20190248898Abstract: The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind somatostatin receptor 2 (SSTR2)Type: ApplicationFiled: April 24, 2019Publication date: August 15, 2019Inventors: Gregory Moore, Rumana Rashid, Sung-Hyung Lee, Paul Foster
-
Publication number: 20190248899Abstract: Described herein are antibodies and mixtures of antibodies optionally produced by a host cell line, nucleic acids encoding the antibodies and mixtures of antibodies, host cells containing such nucleic acids, and methods of treatment using the antibodies, mixtures of antibodies, or nucleic acids encoding the antibodies or mixtures of antibodies. Also described are methods of producing mixtures of antibodies in host cells.Type: ApplicationFiled: May 5, 2017Publication date: August 15, 2019Inventors: Wei Yan, Zhi Liu, Martin J. Pentony
-
Publication number: 20190248900Abstract: Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.Type: ApplicationFiled: August 7, 2017Publication date: August 15, 2019Inventors: Jae Eun Park, Soo Young Kim, Hyun Mi Lee, Si Hyung Lee, Hyun Kyung Lee, Hye-Nan Kim, Jin Chul Youn, Bum-chan Park, Jung Chae Lim, Young-Gyu Cho, Young Woo Park
-
Publication number: 20190248901Abstract: This present disclosure relates to antibodies which bind to soluble forms of MICA and/or MICB protein, compositions comprising the antibodies, and use of the antibodies for diagnostics and in treatment of diseases characterized by elevated level of a MIC protein.Type: ApplicationFiled: October 19, 2017Publication date: August 15, 2019Applicant: Novelogics Biotechnology Inc.Inventor: Ian Wayne CHENEY
-
Publication number: 20190248902Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.Type: ApplicationFiled: December 21, 2018Publication date: August 15, 2019Inventors: Paul Nioi, Peter Coward, Christopher Murawsky, Derek E. Piper, Fernando Garces, Jun Zhang, Yang Li, Brian Mingtung Chan
-
Publication number: 20190248903Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: January 17, 2019Publication date: August 15, 2019Applicant: Genentech, Inc.Inventors: Bing ZHENG, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
-
Publication number: 20190248904Abstract: [Problem] Provided is an anti-human BDCA-2 antibody for preventing or treating an autoimmune disease by binding to a human BDCA-2 to control the function of a plasmacytoid dendritic cell through human BDCA-2.Type: ApplicationFiled: April 15, 2019Publication date: August 15, 2019Applicant: Astellas Pharma Inc.Inventors: Shinsuke NAKAO, Masayuki ITO, Yoshiyuki TENDA
-
Publication number: 20190248905Abstract: The present invention provides a novel IGFR-like receptor and antagonists and agonists for targeting said receptor. Said antagonists and agonists are envisaged for use as a medicament, and in particular for treatment of diabetes.Type: ApplicationFiled: September 7, 2016Publication date: August 15, 2019Inventor: Heiko LICKERT
-
Publication number: 20190248906Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising ?-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising ?-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.Type: ApplicationFiled: February 22, 2019Publication date: August 15, 2019Applicant: Amgen, Inc.Inventors: Yang LI, Jennitte LeAnn STEVENS, Chadwick Terence KING, Ian Nevin FOLTZ, Gunasekaran KANNAN, Junming YIE, Shaw-Fen Sylvia HU
-
Publication number: 20190248907Abstract: The present invention provides antibodies and heterodimeric immunoglobulin molecules, which bind cMET with high affinity and can be used to target cMET expressing tumor cells. The present invention also discloses methods of generating anti-cMET antibody drug conjugates using the inventive antibodies or heterodimeric immunoglobulin molecules as disclosed herein.Type: ApplicationFiled: September 14, 2017Publication date: August 15, 2019Applicant: MERCK PATENT GMBHInventors: Achim DOERNER, Lars TOLEIKIS, Birgit PIATER, Laura RHIEL, Christine KNUEHL, Carolin SELLMANN, Simon KRAH
-
Publication number: 20190248908Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.Type: ApplicationFiled: January 24, 2019Publication date: August 15, 2019Applicant: Five Prime Therapeutics, Inc.Inventors: Brian Wong, Emma Masteller, Kris Reedquist
-
Publication number: 20190248909Abstract: The present disclosure provides methods of selectively depleting islet macrophages in the pancreas comprising disrupting the CSF-1 pathway.Type: ApplicationFiled: February 13, 2019Publication date: August 15, 2019Inventors: Emil R. Unanue, Javier A. Carrero
-
Publication number: 20190248910Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: April 12, 2019Publication date: August 15, 2019Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Publication number: 20190248911Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.Type: ApplicationFiled: April 30, 2019Publication date: August 15, 2019Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
-
Publication number: 20190248912Abstract: Disclosed are an ABCG2 monoclonal antibody having the effects for resisting against tumors and for reversing drug resistance of the tumors, and uses thereof in novel tumor resisting drugs. Also disclosed is a new antigen sequence, used for inducing generation of a monoclonal antibody or a polyclonal antibody for the ABCG2. In addition, disclosed is a hybridoma for generating the ABCG2 monoclonal antibody having the effects for resisting against tumors and for reversing drug resistance of the tumors.Type: ApplicationFiled: September 13, 2017Publication date: August 15, 2019Applicant: PEKING UNVERSITYInventor: Hongying ZHEN
-
Publication number: 20190248913Abstract: The present invention discloses a key mechanism of action of Itolizumab that involves a decrease in an activating ALCAM-CD6 co stimulatory signal by directly reducing CD6 hyperphosphorylation and preventing the docking of key molecules associated with T cell activation and signaling.Type: ApplicationFiled: April 17, 2019Publication date: August 15, 2019Inventors: Pradip NAIR, Arindam SAHA, Ravindra Belavinakodige SADASHIVARAO, Usha BUGHANI, Ramakrishnan MELARKODE
-
Publication number: 20190248914Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.Type: ApplicationFiled: April 23, 2019Publication date: August 15, 2019Inventors: Elizabeth Evans, Ernest S. Smith, Maurice Zauderer
-
Publication number: 20190248915Abstract: Methods, kits, and compositions are provided herein that can be used to treat CD20+cancer using an anti-CD47 agent such as an antibody. The anti-CD47 agent can be used alone or in combination with one or more additional agent such as an anti-CD20 antibody.Type: ApplicationFiled: February 11, 2019Publication date: August 15, 2019Inventors: Mark Ping Chao, Chris Hidemi Mizufune Takimoto, Jens-Peter Volkmer
-
Publication number: 20190248916Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: December 20, 2018Publication date: August 15, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Joerg Benz, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Lydia Jasmin Hanisch, Alexander Bujotzek, Wei Xu
-
Publication number: 20190248917Abstract: The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.Type: ApplicationFiled: April 24, 2019Publication date: August 15, 2019Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20190248918Abstract: The present invention provides antigen-binding polypeptides (e.g., bi-specific antigen-binding polypeptides) that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to HER2 and antagonize HER2 activation. The invention also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen binding polypeptides. Methods of using antigen-binding polypeptide of the invention to treat disease (e.g., cancer) are also encompassed by the invention.Type: ApplicationFiled: January 22, 2019Publication date: August 15, 2019Inventors: Yan CHEN, Richard W. WAGNER, Keming ZHANG, Pascale RICHALET
-
Publication number: 20190248919Abstract: Provided are conjugates including a targeting moiety that binds to a cell surface molecule of a target cell and a target cell surface-editing enzyme. Also provided are compositions and kits that include the conjugates, as well as methods of using the conjugates. Methods of making conjugates are also provided.Type: ApplicationFiled: June 30, 2017Publication date: August 15, 2019Inventors: Elliot C. Woods, Han Xiao, Carolyn R. Bertozzi, Melissa Gray
-
Publication number: 20190248920Abstract: A membrane targeted binding protein that binds to at least one blood coagulation factor, wherein the binding protein has pro-coagulant activity.Type: ApplicationFiled: September 22, 2017Publication date: August 15, 2019Inventors: Peter SCHMIDT, Chao-Guang CHEN, Con PANOUSIS, Louis FABRI
-
Publication number: 20190248921Abstract: The present inventors have completed the present invention by finding that an excellent anticoagulation inhibitory effect is obtained by the administration of an agent inhibiting the activation of protein C.Type: ApplicationFiled: April 23, 2019Publication date: August 15, 2019Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Takehisa Kitazawa, Aya Nakane, Kazutaka Yoshihashi, Tetsuhiro Soeda, Atsushi Muto
-
Publication number: 20190248922Abstract: Affinity ligands useful for mild elution affinity chromatography, including affinity ligands specific for immunoglobulins M, A, and E, are disclosed as are method of identifying and using such affinity ligands.Type: ApplicationFiled: April 2, 2019Publication date: August 15, 2019Inventors: Achim Knappik, Stefan Paschen
-
Publication number: 20190248923Abstract: Provided are bispecific antibody compounds having the Formula I: wherein, FAB1, FAB2, and —X— are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Ax1, and are useful in the treatment of one or more conditions.Type: ApplicationFiled: April 18, 2019Publication date: August 15, 2019Applicant: Sorrento Therapeutics, Inc.Inventors: Yanwen Fu, Gunnar F. Kaufmann, James T. Patterson
-
Publication number: 20190248924Abstract: The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.Type: ApplicationFiled: April 22, 2019Publication date: August 15, 2019Inventor: Chengbin Wu
-
Publication number: 20190248925Abstract: Provided is a nitrocellulose with incorporated binders, the binders being plasticisers or resins, in the form of granules (NPG/NRG), optionally with addition of pigments (NPPG), with diameters of between 0.4 and 2.0 mm, which has a uniform particle size and low water content, for use in ink, varnish and sealant compositions, for the fields of: nail varnishes, automotive respraying, graphic printing on flexible films, such as flexography, rotogravure and laminating (such as, for example, BOPP, metallized BOPP, PE, PET, inter alia), wood surfaces, paper, glass, plastics, leather, metalworking, textiles, amongst other uses.Type: ApplicationFiled: June 14, 2017Publication date: August 15, 2019Inventors: Ludmila De Carvalho FIDALE, Reginaldo Faichel Da SILVA, Oscimar TORRES, Paula Decot GALGANO, Fernando Antonio Cardoso FERREIRA
-
Publication number: 20190248926Abstract: Disclosed is a method for preparing a resistant dextrin product by using compound enzyme treatment. Starch is first subjected to high-temperature acidolysis to obtain pyrodextrin which is used as the substrate for the enzyme treatment. A compound enzyme reaction system including a starch branching enzyme and a CGTase is used for preparing the resistant dextrin product. The starch branching enzyme and the CGTase are added simultaneously or sequentially to treat the pyrodextrin to further increase the content of the resistant component in the product. The content of the resistant component of the enzyme treated product reaches up to 65.3%, a 21.3% increase from that of the pyrodextrin before the enzyme treatment.Type: ApplicationFiled: November 20, 2018Publication date: August 15, 2019Applicant: Jiangnan UniversityInventors: Jing Wu, Sheng Chen, Jun Liu
-
Publication number: 20190248927Abstract: The invention relates to a method for producing a polymer by means of nitroxyl-controlled polymerisation. According to the invention, a mixture is initiated which contains at least one radically polymerisable monomer and additionally contains at least one initiator, at least one reactive agent that converts at least one portion of the alkoxyamine end groups produced during the radical polymerisation into a non-polymerisable group, and at least one additive that accelerates the hydroxyl-controlled polymerisation and/or the conversion of the alkoxyamine end groups into a non-polymerisable group.Type: ApplicationFiled: October 27, 2017Publication date: August 15, 2019Applicant: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E. V.Inventors: Roland KLEIN, Markus MAZUROWSKI, Konrad BURLON, Matthias WITTEMANN, Rudolf PFAENDNER
-
Publication number: 20190248928Abstract: The present invention provides an olefin coordination polymerization catalyst and use thereof. The composition of the raw materials of the olefin coordination polymerization catalyst comprises: a main catalyst and a cocatalyst, wherein a molar ratio of the transition metal halide in the main catalyst to the cocatalyst is 1:10-500; and the composition of the raw materials of the main catalyst comprises a magnesium compound, a transition metal halide, an alcohol having 2 to 15 carbon atoms, and a star-shaped organosiloxane compound in a molar ratio of 1:1-40:0.01-10:0.001-10; and the cocatalyst comprises an organoaluminum compound. The above olefin coordination polymerization catalyst is used as a catalyst for ethylene polymerization, propylene polymerization, and copolymerization of ethylene or propylene with an ?-olefin. The olefin polymerization catalyst of the present invention has good catalytic activity.Type: ApplicationFiled: October 12, 2018Publication date: August 15, 2019Inventors: Jianjun Yi, Mingge Zhang, Hongming Li, Tianxu Sun, Yuan Yuan, Yisen Wang, Qigu Huang, Runcong Zhang, Jing Wang, Yanpei Nie
-
Publication number: 20190248929Abstract: This invention relates to a supported catalyst system and process for use thereof. In particular, the catalyst system includes a benzindenyl transition metal complex, a support material and an activator. The catalyst system may be used for preparing polyolefins, such as polyethylene.Type: ApplicationFiled: February 7, 2019Publication date: August 15, 2019Inventor: Laughlin G. McCullough
-
Publication number: 20190248930Abstract: A process for the preparation of a solid catalyst component for the homo or copolymerization of olefins, wherein the solid catalyst component is made from or contains Mg, Ti, halogen and an electron donor selected from cycloalkyl ethers, wherein the process includes the steps of (a) dissolving a Mg based compound and a TiCl3 based compound in a liquid medium further made from or containing a cycloalkyl ether and a compound of formula R2OH where R2 is a C1-C20 hydrocarbon group, in which the Ti/Mg molar ratio ranges from 0.1 to 0.5, the cycloalkyl ether/Mg ratio ranges from 1 to 4 and the ROH/Mg molar ratio ranges from 1 to 4; and (b) adding, to the solution coming from step (a), SiCl4 in an amount such that the R2OH/SiCl4 molar ratio ranges from 0.5 to 1.5 and maintaining the temperature in the range 50-150° C. thereby precipitating the solid catalyst component particles.Type: ApplicationFiled: September 25, 2017Publication date: August 15, 2019Applicant: BASELL POLIOLEFINE ITALIA S.R.L.Inventors: SIMONA GUIDOTTI, TIZIANO DALL'OCCO, DARIO LIGUORI, GIAMPIERO MORINI
-
Publication number: 20190248931Abstract: Provided is a dispersion assistant useful for suspension polymerization of vinyl-based compounds. The dispersion assistant comprises a polyvinyl alcohol-based polymer (A) comprising a constituent unit represented by the general formula (1) shown below at 0.1 to 10 mol % per polyvinyl alcohol monomer unit and having a saponification degree of 15 to 70 mol %. (In the formula, R denotes an alkyl group.Type: ApplicationFiled: October 17, 2017Publication date: August 15, 2019Applicant: Japan Vam & Poval Co., Ltd.Inventors: Takehiro Omori, Yoshiaki Kozuka
-
Publication number: 20190248932Abstract: A formulation for a photopolymer composite material for a 3D printing system includes an acrylate oligomer, an inorganic hydrate, a reinforcing filler, and an ultraviolet (UV) initiator. In the formulation the acrylate oligomer may be found in the range between about 20.0-60.0 w % of the formulation. The inorganic hydrate may be found in the range between about 20.0-50.0 w % of the formulation. The reinforcing filler may be found in the range between about 5.0-60.0 w % of the formulation, and the UV initiator may be found in the range between about 0.001-0.5 w % of the formulation. A method of generating a formulation of a photopolymer composite material for use in a 3D printing system includes using an acrylate oligomer, an inorganic hydrate, a reinforcing filler, and an ultraviolet (UV) initiator.Type: ApplicationFiled: February 14, 2019Publication date: August 15, 2019Inventors: Vasily Korshikov, Anna Trushina, Dmitry Starodubtsev, Slava Solonitsyn, Igor Kovalev
-
Publication number: 20190248933Abstract: The invention relates to a process for the production of ultra high molecular weight polyethylene in the presence of a catalyst system that comprises (I) the solid reaction product obtained from the reaction of a) a hydrocarbon solution containing 1) an organic oxygen containing magnesium compound or a halogen containing magnesium compound and 2) an organic oxygen containing titanium compound and b) an aluminium compound of the formula AIRaX(3-a) where R is a hydrocarbylgroup containing (3-10) carbon atoms, X is an halogenide and 0<a<3 and (I!) an aluminium compound having the formula AIR3 in which R is a wherein the molar ratio of aluminium from (b): titanium from (a) is higher than 3:1 and the average particle size of the catalyst ranges between 0.1 ?m and 1.Type: ApplicationFiled: October 24, 2017Publication date: August 15, 2019Inventors: Remy Peter Theresia Smeets, Nicolaas Hendrika Friederichs, Robert Lap Key Chan
-
Publication number: 20190248934Abstract: A process to produce a branched ethylene-?-olefin diene elastomer comprising combining a catalyst precursor and an activator with a feed comprising ethylene, C3 to C12 ?-olefins, and a dual-polymerizable diene to obtain a branched ethylene-?-olefin diene elastomer; where the catalyst precursor is selected from pyridyldiamide and quinolinyldiamido transition metal complexes. The branched ethylene-?-olefin diene elastomer may comprise within a range from 40 to 80 wt % of ethylene-derived units by weight of the branched ethylene-?-olefin diene elastomer, and 0.1 to 2 wt % of singly-polymerizable diene derived units, 0.1 to 2 wt % of singly-polymerizable diene derived units, and the remainder comprising C3 to C12 ?-olefin derived units, wherein the branched ethylene-?-olefin diene elastomer has a weight average molecular weight (Mw) within a range from 100 kg/mole to 300 kg/mole, an average branching index (g?avg) of 0.9 or more, and a branching index at very high Mw (g?1000) of less than 0.9.Type: ApplicationFiled: January 17, 2019Publication date: August 15, 2019Inventors: Crisita Carmen H. Atienza, Rhutesh K. Shah, Ron Walker, John R. Hagadorn, Sudhin Datta
-
Publication number: 20190248935Abstract: A process to produce a branched ethylene-?-olefin diene elastomer comprising combining a catalyst precursor and an activator with a feed comprising ethylene, C3 to C12 ?-olefins, and a dual-polymerizable diene to obtain a branched ethylene-?-olefin diene elastomer; where the catalyst precursor is selected from pyridyldiamide and quinolinyldiamido transition metal complexes. The branched ethylene-?-olefin diene elastomer may comprise within a range from 40 to 80 wt % of ethylene-derived units by weight of the branched ethylene-?-olefin diene elastomer, and 0.1 to 2 wt % of singly-polymerizable diene derived units, 0.1 to 2 wt % of singly-polymerizable diene derived units, and the remainder comprising C3 to C12 ?-olefin derived units, wherein the branched ethylene-?-olefin diene elastomer has a weight average molecular weight (Mw) within a range from 100 kg/mole to 300 kg/mole, an average branching index (g?avg) of 0.9 or more, and a branching index at very high Mw (g?1000) of less than 0.9.Type: ApplicationFiled: January 17, 2019Publication date: August 15, 2019Inventors: Crisita Carmen H. Atienza, Rhutesh K. Shah, Ron Walker, John R. Hagadorn, Sudhin Datta
-
Publication number: 20190248936Abstract: A process for making a poly alpha-olefin (PAO) having a relatively high vinylidene content (or combined vinylidene and tri-substituted vinylene content) and a relatively low vinyl and/or di-substituted vinylene content, as well as a relatively low molecular weight. The process includes: contacting a feed containing a C2-C32 alpha-olefin with a catalyst system comprising activator and a bis-cyclopentadienyl metallocene compound, typically a cyclopentadienyl-benzindenyl group 4 transition metal compound.Type: ApplicationFiled: February 7, 2019Publication date: August 15, 2019Inventors: Jian Yang, Jo Ann M. Canich, Hua Zhou, Jennifer L. Rapp
-
Publication number: 20190248937Abstract: Catalyst activators and methods for their preparation and their use in processes for polymerizing olefins are described. In particular, catalyst activators derived from aluminum alkyls and their use with metallocene type catalyst systems and/or conventional-type transition metal catalyst systems are described.Type: ApplicationFiled: April 24, 2019Publication date: August 15, 2019Applicant: Univation Technologies, LLCInventors: Ian M. Munro, Kevin J. Cann
-
Publication number: 20190248938Abstract: The invention provides a fluoroelastomer composition capable of providing a molded article that is inexpensive and has excellent heat-aging resistance. The fluoroelastomer composition is a peroxide-crosslinkable fluoroelastomer composition containing a fluorine-containing elastomer that contains 25 to 90 mol % of a unit of vinylidene fluoride, 10 to 75 mol % of a unit of a fluorine-containing monomer other than the vinylidene fluoride, 0 to 10 mol % of a unit of a fluorine-free monomer copolymerizable with the vinylidene fluoride, and 0.1% by mass or less of an iodine atom and a bromine atom; an organic peroxide having a specific structure; and a co-crosslinking agent. The organic peroxide is present in an amount of 0.3 to 10 parts by mass relative to 100 parts by mass of the fluorine-containing elastomer.Type: ApplicationFiled: January 30, 2019Publication date: August 15, 2019Applicant: DAIKIN INDUSTRIES, LTD.Inventor: Kazuyoshi KAWASAKI
-
Publication number: 20190248939Abstract: The present invention relates to a water-absorbing polymer and to a process for preparation, including finishing the water-absorbing polymer, with 0.0001 to 3% by weight, of a peroxo compound, based on the acrylic acid, after the polymerization is treated, and to a process for producing a hydrogel polymer, to the product of the process and to use.Type: ApplicationFiled: April 25, 2019Publication date: August 15, 2019Inventors: Christoph Loick, Scott Smith
-
Publication number: 20190248940Abstract: The present disclosure provides a method for efficiently producing an ?-alkylstyrene ?-chloroacrylate copolymer having a high monomer conversion rate. According to the present disclosure, the method for producing a copolymer containing 30 mol % to 70 mol % of an ?-alkylstyrene unit and 30 mol % to 70 mol % of an ?-chloroacrylate unit includes a step of performing solution polymerization of a monomer composition containing ?-alkylstyrene and ?-chloroacrylate, and uses ketone as a polymerization solvent for the solution polymerization.Type: ApplicationFiled: March 3, 2017Publication date: August 15, 2019Applicant: ZEON CORPORATIONInventors: Kakuei OZAWA, Nobunori ABE
-
Publication number: 20190248941Abstract: This invention relates generally to the field of quasicrystalline structures. In preferred embodiments, the stopgap structure is more spherically symmetric than periodic structures facilitating the formation of stopgaps in nearly all directions because of higher rotational symmetries. More particularly, the invention relates to the use of quasicrystalline structures for optical, mechanical, electrical and magnetic purposes. In some embodiments, the invention relates to manipulating, controlling, modulating and directing waves including electromagnetic, sound, spin, and surface waves, for pre-selected range of wavelengths propagating in multiple directions.Type: ApplicationFiled: February 27, 2019Publication date: August 15, 2019Inventors: Paul Joseph Steinhardt, Paul Michael Chaikin, Weining Man
-
Publication number: 20190248942Abstract: A material non-adhesive to a biological substance containing: a polymer compound (A) which includes a repeating unit derived from a sulfobetaine monomer represented by Formula (I) or (II). In the formulae, R1 represents a methyl group, an ethyl group, an n-propyl group, or an isopropyl group, a plurality of R1's may be the same as or different from each other. R2 represents a hydrogen atom or a methyl group. n represents an integer of 2 to 4. L represents a linear or branched alkylene group having 3 or 4 carbon atoms.Type: ApplicationFiled: April 25, 2019Publication date: August 15, 2019Applicant: FUJIFILM CorporationInventor: Kiyotaka FUKAGAWA
-
Publication number: 20190248943Abstract: A method of preparing a flame retardant grafted polyolefin resin is provided. The method includes a step of reacting in an extrusion barrel a reactive polyolefin and a monomeric flame retardant agent to form the flame retardant grafted polyolefin resin. The reactive polyolefin has a functional group including a moiety selected from the group consisting of anhydrides, epoxies, carboxylic acids, ketones, and isocyanates. The monomeric flame retardant agent has an amine functional group. The method also includes a step of extruding the flame retardant grafted polyolefin resin. Also provided is a flame retardant grafted polyolefin resin that can be made according to the method. Further provided is a flame retardant cable that incorporates can incorporate the flame retardant grafted polyolefin resin.Type: ApplicationFiled: April 25, 2019Publication date: August 15, 2019Inventors: Xiaole Cheng, Dayue Jiang
-
Publication number: 20190248944Abstract: [Problem] To provide a conductive resin composition for electrodes which is excellent in dispersibility and oxidation resistance. To provide: an electrode composition employing the conductive resin composition for electrodes and having a low viscosity; an electrode employing the electrode composition and having a low electrode plate resistance; and a lithium ion battery having a high energy density, high output characteristics and a high cyclability.Type: ApplicationFiled: July 14, 2017Publication date: August 15, 2019Applicant: Denka Company LimitedInventors: Tatsuya NAGAI, Takuya NARUTOMI, Tetsuya ITO, Hiroshi YOKOTA
-
Publication number: 20190248945Abstract: A (meth)acrylic silicone graft (co)polymer having a unit represented by the following formula (I), a structure represented by the following formula (III) at one terminal, and a structure represented by the following formula (IV) at the other terminal, wherein A is a group having a linear organopolysiloxane structure represented by the following formula (1) or a group having a dendritic organopolysiloxane structure represented by the following formula (2-1) or (2-2), X? is a group as defined for A, wherein Z is a divalent organic group, Q is a group represented by the following formula (2), D is a (3c+1)-valent organopolysiloxanyl group which has a hierachial order of c, 3c means 3 raised to the power of c, c is an integer of from 1 to 8.Type: ApplicationFiled: February 7, 2019Publication date: August 15, 2019Applicant: SHIN-ETSU CHEMICAL CO., LTD.Inventor: Ryunosuke HATA